13 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals REGN over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 9 | 1 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 4 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $1072.38, a high estimate of $1189.00, and a low estimate of $720.00. This upward trend is evident, with the current average reflecting a 6.11% increase from the previous average price target of $1010.67.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Geoff Meacham | B of A Securities | Raises | Underperform | $720.00 | $710.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1189.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $1115.00 | $1104.00 |
| William Pickering | Bernstein | Announces | Outperform | $1125.00 | - |
| Aaron Gal | Bernstein | Announces | Outperform | $1125.00 | - |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1184.00 | $1096.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $925.00 | $850.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1110.00 | $1076.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $1082.00 | $1055.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1076.00 | - |
| Carter Gould | Barclays | Raises | Overweight | $1020.00 | $935.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regeneron Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Regeneron Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Regeneron Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
All You Need to Know About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Breaking Down Regeneron Pharmaceuticals's Financial Performance
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 0.58%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 33.77%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 3.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
